Low IDL causes: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
Ochuko Ajari (talk | contribs) |
||
| Line 35: | Line 35: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Drug Side Effect''' | | '''Drug Side Effect''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| Estrogen plus simvastatin combination therapy, extended-release niacin/laropiprant and simvastatin, [[lovastatin]], [[pravastatin]], [[statins]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| Line 51: | Line 51: | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Gastroenterologic''' | | '''Gastroenterologic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| [[Lipoprotein lipase deficiency]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
| '''Genetic''' | | '''Genetic''' | ||
|bgcolor="Beige"| | |bgcolor="Beige"| Familial apolipoprotein AI and apolipoprotein CIII deficiency, [[lipoprotein lipase deficiency]] | ||
|- | |- | ||
|-bgcolor="LightSteelBlue" | |-bgcolor="LightSteelBlue" | ||
Revision as of 19:59, 5 November 2013
|
Intermediate Density Lipoprotein Microchapters |
|
Clinical Correlation |
|---|
|
Treatment |
|
Case Studies |
|
Low IDL causes On the Web |
|
American Roentgen Ray Society Images of Low IDL causes |
|
Directions to Hospitals Treating Intermediate density lipoprotein |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
There are no life threatening causes of low IDL.
Common Causes
Causes by Organ System
| Cardiovascular | No underlying causes |
| Chemical/Poisoning | No underlying causes |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | Estrogen plus simvastatin combination therapy, extended-release niacin/laropiprant and simvastatin, lovastatin, pravastatin, statins |
| Ear Nose Throat | No underlying causes |
| Endocrine | No underlying causes |
| Environmental | No underlying causes |
| Gastroenterologic | Lipoprotein lipase deficiency |
| Genetic | Familial apolipoprotein AI and apolipoprotein CIII deficiency, lipoprotein lipase deficiency |
| Hematologic | No underlying causes |
| Iatrogenic | No underlying causes |
| Infectious Disease | No underlying causes |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | No underlying causes |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | No underlying causes |
| Renal/Electrolyte | No underlying causes |
| Rheumatology/Immunology/Allergy | No underlying causes |
| Sexual | No underlying causes |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | No underlying causes |
Causes in Alphabetical Order
- Estrogen plus simvastatin combination therapy[1]
- Extended-release niacin/laropiprant and simvastatin[2]
- Familial apolipoprotein AI and apolipoprotein CIII deficiency[3]
- Lipoprotein lipase deficiency
- Lovastatin[4]
- Pravastatin[5][6]
- Statins
References
- ↑ Wakatsuki A, Okatani Y, Ikenoue N (2000). "Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia". Atherosclerosis. 150 (1): 103–11. PMID 10781640.
- ↑ Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y (2012). "Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia". J Clin Lipidol. 6 (3): 235–43. doi:10.1016/j.jacl.2011.11.004. PMID 22658147.
- ↑ Forte TM, Nichols AV, Krauss RM, Norum RA (1984). "Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis". J Clin Invest. 74 (5): 1601–13. doi:10.1172/JCI111576. PMC 425337. PMID 6501564.
- ↑ Mack WJ, Krauss RM, Hodis HN (1996). "Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression". Arterioscler Thromb Vasc Biol. 16 (5): 697–704. PMID 8963728.
- ↑ Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
- ↑ Lee SJ, Sacks FM (2003). "Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus". Am J Cardiol. 92 (2): 121–4. PMID 12860210.